ARTICLE | Company News
Aduro Biotech, Novartis deal
May 23, 2016 7:00 AM UTC
Aduro received a $35 million milestone payment from Novartis under a 2015 deal to develop receptor agonists of STING ( transmembrane protein 173; TMEM173) generated using Aduro’s cyclic dinucleotide ...